search.noResults

search.searching

saml.title
dataCollection.invalidEmail
note.createNoteMessage

search.noResults

search.searching

orderForm.title

orderForm.productCode
orderForm.description
orderForm.quantity
orderForm.itemPrice
orderForm.price
orderForm.totalPrice
orderForm.deliveryDetails.billingAddress
orderForm.deliveryDetails.deliveryAddress
orderForm.noItems
eamesBot/Shutterstock.com


Clinical supplies & logistics Breaking the


ood health, so the saying goes, is priceless. But beyond the proverbs, the opposite is true. Medicines cost money, and the figures are rising all the time. And if that’s true at the end of the drug supply chain – the price of new drugs in the US jumped by more than 35% in 2023 – something similar is happening at the beginning too. Once again, the numbers here are clear, with the US Bureau of Labor Statistics reporting that per-patient clinical trial costs rose over fourfold between 1989 and 2011, even as the global spend is expected to reach almost $70bn by 2025.


G


There are plenty of ways to understand this increase, from patient recruitment to study design to operational expenditure. Whatever the cause, at any rate, the repercussions of spiralling costs are clear, not least


cost barrier


In the ever changing landscape of clinical trials, markets have increasingly seen associated costs rise over the years with an estimated 140% increase in the past decade. With roughly $2.6bn – and 15 years to bring a new drug to market – what can be done to cut costs and raise efficiency? Andrea


Valentino talks to Dawn Anderson, managing director, Deloitte Life Sciences R&D and Salman Shah, R&D consulting field of play leader and principal at EY, to find out how optimised clinical supply sourcing, and the clever use of technology and data, can help keep prices down.


when it comes to the sorts of projects pharma firms approve. “We are seeing biopharma clients having to cut costs and reduce the size and prioritise their drug development pipelines,” explains Dawn Anderson, a clinical trial expert at Deloitte, adding that “fewer clinical trials” could ultimately be green-lit. Once you factor in the impact of expensive trials on patients themselves, it becomes obvious that soaring trial costs can have severe real-world consequences. Even so, the situation is far from hopeless. Between limiting waste via digitalised drug sourcing, and


22


Clinical Trials Insight / www.worldpharmaceuticals.net


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37